Abstract
Clinical course of patients with advanced non-small cell lung cancer (aNSCLC) has tremendously changed the last decade due to immune checkpoint inhibitors (ICIs). However, clinical useful biomarkers remain an unmet need. Recently, our group has proposed a new score, Patras Immunotherapy Score (PIOS), based on the results of aNSCLC patients treated with ICIs monotherapy. The objective of the current study was to assess the clinical significance of PIOS formula in aNSCLC patients treated with combination of immunotherapy with chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
